Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study

Bruna Regis de Paiva; Marta Esgalhado; Natália Alvarenga Borges; Julie Ann Kemp; Gutemberg Alves; Paulo Emílio Corrêa Leite; Renata Macedo; Ludmila F.M.F. Cardozo; Jessyca Sousa de Brito; Denise Mafra

doi:10.1007/s11255-020-02392-3

Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study

Bruna Regis de Paiva, Marta Esgalhado, Natália Alvarenga Borges, Julie Ann Kemp, Gutemberg Alves, Paulo Emílio Corrêa Leite, Renata Macedo, Ludmila F.M.F. Cardozo, Jessyca Sousa de Brito, Denise Mafra

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Purpose: In chronic kidney disease (CKD) patients, dysbiosis is associated with inflammation and cardiovascular risk, so many nutritional strategies are being studied to reduce these complications. Resistant starch (RS) can be considered a prebiotic that promotes many benefits, including modulation of gut microbiota which is linked to immune-modulatory effects. The aim of this study was to evaluate the effects of RS supplementation on proinflammatory cytokines in CKD patients on hemodialysis (HD). Methods: A double-blind, placebo-controlled, randomized trial was conducted with sixteen HD patients (55.3 ± 10.05 years, body mass index (BMI) 25.9 ± 5.42 kg/m², 56% men, time on dialysis 38.9 ± 29.23 months). They were allocated to the RS group (16 g RS/day) or placebo group (manioc flour). The serum concentration of ten cytokines and growth factors was detected through a multiparametric immunoassay based on XMap-labeled magnetic microbeads (Luminex Corp, USA) before and after 4 weeks with RS supplementation. Results: After RS supplementation, there was a reduction of Regulated upon Activation, Normal T-Cell Expressed and Secreted (p < 0.001), platelet-derived growth factor (two B subunits) (p = 0.014) and interferon-inducible protein 10 (IP-10) (p = 0.027). The other parameters did not change significantly. Conclusion: This preliminary result indicates that RS may contribute to a desirable profile of inflammatory markers in CKD patients.

Original language	English
Pages (from-to)	549-555
Number of pages	7
Journal	International Urology and Nephrology
Volume	52
Issue number	3
DOIs	https://doi.org/10.1007/s11255-020-02392-3
Publication status	Published - 1 Mar 2020
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2020, Springer Nature B.V.

Funding

The authors would like to thank all the patients who participated in the study, and Sandra Marinho, Najla Elias Farage, Mariana Zogbi, Maria Clara Testa and all the Renalcor clinic staff for the remarkable help in this study. Additionally, we also would like to thank Unidade de Pesquisa Clínica, Laboratório de Nutrição Experimental, Laboratório de Alimentos e Dietética, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The RS used for supplementation was kindly provided by Ingredion®. The authors would like to thank all the patients who participated in the study, and Sandra Marinho, Najla Elias Farage, Mariana Zogbi, Maria Clara Testa and all the Renalcor clinic staff for the remarkable help in this study. Additionally, we also would like to thank Unidade de Pesquisa Clínica, Laboratório de Nutrição Experimental, Laboratório de Alimentos e Dietética, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The RS used for supplementation was kindly provided by Ingredion. ®

Funders	Funder number
Maria Clara Testa
Mariana Zogbi
Najla Elias Farage
Sandra Marinho
Unidade de Pesquisa Clínica
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Keywords

Chronic kidney disease
Cytokines
Hemodialysis
Inflammation
Resistant starch

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11255-020-02392-3

Cite this

@article{d7898389a29f4f29b362ad0f8763795b,

title = "Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study",

abstract = "Purpose: In chronic kidney disease (CKD) patients, dysbiosis is associated with inflammation and cardiovascular risk, so many nutritional strategies are being studied to reduce these complications. Resistant starch (RS) can be considered a prebiotic that promotes many benefits, including modulation of gut microbiota which is linked to immune-modulatory effects. The aim of this study was to evaluate the effects of RS supplementation on proinflammatory cytokines in CKD patients on hemodialysis (HD). Methods: A double-blind, placebo-controlled, randomized trial was conducted with sixteen HD patients (55.3 ± 10.05 years, body mass index (BMI) 25.9 ± 5.42 kg/m2, 56% men, time on dialysis 38.9 ± 29.23 months). They were allocated to the RS group (16 g RS/day) or placebo group (manioc flour). The serum concentration of ten cytokines and growth factors was detected through a multiparametric immunoassay based on XMap-labeled magnetic microbeads (Luminex Corp, USA) before and after 4 weeks with RS supplementation. Results: After RS supplementation, there was a reduction of Regulated upon Activation, Normal T-Cell Expressed and Secreted (p < 0.001), platelet-derived growth factor (two B subunits) (p = 0.014) and interferon-inducible protein 10 (IP-10) (p = 0.027). The other parameters did not change significantly. Conclusion: This preliminary result indicates that RS may contribute to a desirable profile of inflammatory markers in CKD patients.",

keywords = "Chronic kidney disease, Cytokines, Hemodialysis, Inflammation, Resistant starch",

author = "{de Paiva}, {Bruna Regis} and Marta Esgalhado and Borges, {Nat{\'a}lia Alvarenga} and Kemp, {Julie Ann} and Gutemberg Alves and Leite, {Paulo Em{\'i}lio Corr{\^e}a} and Renata Macedo and Cardozo, {Ludmila F.M.F.} and {de Brito}, {Jessyca Sousa} and Denise Mafra",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Nature B.V.",

year = "2020",

month = mar,

day = "1",

doi = "10.1007/s11255-020-02392-3",

language = "English",

volume = "52",

pages = "549--555",

journal = "International Urology and Nephrology",

issn = "0301-1623",

publisher = "Springer Science and Business Media B.V.",

number = "3",

}

TY - JOUR

T1 - Resistant starch supplementation attenuates inflammation in hemodialysis patients

T2 - a pilot study

AU - de Paiva, Bruna Regis

AU - Esgalhado, Marta

AU - Borges, Natália Alvarenga

AU - Kemp, Julie Ann

AU - Alves, Gutemberg

AU - Leite, Paulo Emílio Corrêa

AU - Macedo, Renata

AU - Cardozo, Ludmila F.M.F.

AU - de Brito, Jessyca Sousa

AU - Mafra, Denise

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Purpose: In chronic kidney disease (CKD) patients, dysbiosis is associated with inflammation and cardiovascular risk, so many nutritional strategies are being studied to reduce these complications. Resistant starch (RS) can be considered a prebiotic that promotes many benefits, including modulation of gut microbiota which is linked to immune-modulatory effects. The aim of this study was to evaluate the effects of RS supplementation on proinflammatory cytokines in CKD patients on hemodialysis (HD). Methods: A double-blind, placebo-controlled, randomized trial was conducted with sixteen HD patients (55.3 ± 10.05 years, body mass index (BMI) 25.9 ± 5.42 kg/m2, 56% men, time on dialysis 38.9 ± 29.23 months). They were allocated to the RS group (16 g RS/day) or placebo group (manioc flour). The serum concentration of ten cytokines and growth factors was detected through a multiparametric immunoassay based on XMap-labeled magnetic microbeads (Luminex Corp, USA) before and after 4 weeks with RS supplementation. Results: After RS supplementation, there was a reduction of Regulated upon Activation, Normal T-Cell Expressed and Secreted (p < 0.001), platelet-derived growth factor (two B subunits) (p = 0.014) and interferon-inducible protein 10 (IP-10) (p = 0.027). The other parameters did not change significantly. Conclusion: This preliminary result indicates that RS may contribute to a desirable profile of inflammatory markers in CKD patients.

AB - Purpose: In chronic kidney disease (CKD) patients, dysbiosis is associated with inflammation and cardiovascular risk, so many nutritional strategies are being studied to reduce these complications. Resistant starch (RS) can be considered a prebiotic that promotes many benefits, including modulation of gut microbiota which is linked to immune-modulatory effects. The aim of this study was to evaluate the effects of RS supplementation on proinflammatory cytokines in CKD patients on hemodialysis (HD). Methods: A double-blind, placebo-controlled, randomized trial was conducted with sixteen HD patients (55.3 ± 10.05 years, body mass index (BMI) 25.9 ± 5.42 kg/m2, 56% men, time on dialysis 38.9 ± 29.23 months). They were allocated to the RS group (16 g RS/day) or placebo group (manioc flour). The serum concentration of ten cytokines and growth factors was detected through a multiparametric immunoassay based on XMap-labeled magnetic microbeads (Luminex Corp, USA) before and after 4 weeks with RS supplementation. Results: After RS supplementation, there was a reduction of Regulated upon Activation, Normal T-Cell Expressed and Secreted (p < 0.001), platelet-derived growth factor (two B subunits) (p = 0.014) and interferon-inducible protein 10 (IP-10) (p = 0.027). The other parameters did not change significantly. Conclusion: This preliminary result indicates that RS may contribute to a desirable profile of inflammatory markers in CKD patients.

KW - Chronic kidney disease

KW - Cytokines

KW - Hemodialysis

KW - Inflammation

KW - Resistant starch

UR - http://www.scopus.com/inward/record.url?scp=85079146148&partnerID=8YFLogxK

U2 - 10.1007/s11255-020-02392-3

DO - 10.1007/s11255-020-02392-3

M3 - Article

C2 - 32008198

AN - SCOPUS:85079146148

SN - 0301-1623

VL - 52

SP - 549

EP - 555

JO - International Urology and Nephrology

JF - International Urology and Nephrology

IS - 3

ER -

Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this